Who We Are
Ocular diseases, such as wet age-related macular degeneration, diabetic macular edema, and diabetic retinopathy, are debilitating and can deprive people of their vision.
Current treatments have limited durability and are unable to correct the underlying disease pathology resulting in an untenable treatment burden and failure to fully restore vision.
Our business is to develop safer, more efficacious, and longer-lasting therapeutics for ocular diseases.
Scott Ferguson, PhD
Co-Founder & CEO
For nearly a decade, Scott has driven the realization of innovative solutions to major problems in health care. Prior to Aptitude, Scott has played an active role in multiple life science ventures, pioneered technologies for personalized medicine, and authored several patents, and highly-cited journal publications.
Jackson Gong, PhD
Co-Founder & COO
Trained in both life science research and management, Jackson brings to Aptitude both scientific and operational expertise. He has published 10+ peer-reviewed papers and co-invented several patents that serve as the foundation of Aptitude technology.
JP Wang, PhD
Co-Founder & CSO
JP has focused his career on applying engineering principles to biological problems that promote scientific discovery and the development of new biomedical technologies and therapies. He has authored multiple peer-reviewed journal publications, and is the lead inventor of Aptitude’s revolutionary aptamer discovery technology.